ADCdb: the database of antibody–drug conjugates
Authors:
Open Access
- 13 October 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1097-D1109
Abstract
Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which, via their antibody (mAb) component, deliver and release their potent warhead (a.k.a. payload) at the disease site, thereby simultaneously improving the efficacy of delivered therapy and reducing its off-target toxicity. To design ADCs of promising efficacy, it is crucial to have the critical data of pharma-information and biological activities for each ADC. However, no such database has been constructed yet. In this study, a database named ADCdb focusing on providing ADC information (especially its pharma-information and biological activities) from multiple perspectives was thus developed. Particularly, a total of 6572 ADCs (359 approved by FDA or in clinical trial pipeline, 501 in preclinical test, 819 with in-vivo testing data, 1868 with cell line/target testing data, 3025 without in-vivo/cell line/target testing data) together with their explicit pharma-information was collected and provided. Moreover, a total of 9171 literature-reported activities were discovered, which were identified from diverse clinical trial pipelines, model organisms, patient/cell-derived xenograft models, etc. Due to the significance of ADCs and their relevant data, this new database was expected to attract broad interests from diverse research fields of current biopharmaceutical drug discovery. The ADCdb is now publicly accessible at: https://idrblab.org/adcdb/.Keywords
Funding Information
- Natural Science Foundation of China (82173660, 81973172, 82373790, 82274020, 81973396, 82373790, U1909208, 22220102001)
- Natural Science Fund for Distinguished Young Scholars of Zhejiang (LR21H300003, LR21H300001)
- Key R&D Program of Zhejiang Province (2023C03111)
This publication has 97 references indexed in Scilit:
- Analysis and prediction of protein folding energy changes upon mutation by element specific persistent homologyBioinformatics, 2017
- DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistanceInternational Journal of Cancer, 2017
- Strategies and challenges for the next generation of antibody–drug conjugatesNature Reviews Drug Discovery, 2017
- Antibody-drug conjugates: recent advances in conjugation and linker chemistriesProtein & Cell, 2016
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Clinical Cancer Research, 2016
- ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval TrialsAnnals of Internal Medicine, 2016
- Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneityCancer Science, 2016
- Antibody–drug conjugates for cancer therapyThe Lancet Oncology, 2016
- Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic AgentsJournal of Medicinal Chemistry, 2015
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer2014